

Analysis of features among BRCA1-, BRCA2- and non-BRCA1/2-associated cancers and in unselected cancers

Feature	N (frequency, %)			Unselected	P
	BRCA1	BRCA2	Non-BRCA1/2		
Histology					
Ca ductale	37 (72.5)	37 (62.7)	102 (67.1)	561 (65.1)	0.013*, 0.001**
Ca lobulare	8 (15.7)	17 (28.8)	30 (19.7)	219 (25.4)	
Ca medullare	5 (9.8)	-	3 (2.0)	20 (2.3)	
Others	1 (2.0)	5 (8.5)	17 (11.2)	62 (7.2)	
Grade					
I	3 (6.1)	12 (23.1)	46 (32.4)	152 (23.3)	≤ 0.0005*, <0.0005**, 0.009****
II	11 (22.4)	26 (50.1)	66 (46.5)	289 (44.4)	
III	35 (71.4)	14 (26.9)	30 (21.1)	210 (32.3)	
I-II	14 (28.6)	38 (73.1)	112 (78.9)	441 (67.7)	
Immunohistochemistry					
ER-	28 (66.7)	17 (32.1)	40 (27.0)	167 (19.4)	≤ 0.0005*, <0.0005**, 0.026***, 0.035****
ER+	14 (33.3)	36 (67.9)	108 (73.0)	692 (80.6)	
PgR	37 (84.1)	28 (51.9)	67 (45.3)	312 (36.2)	≤ 0.0005*, <0.0005**, 0.021***, 0.036****
PgR+	7 (15.9)	26 (48.1)	81 (54.7)	549 (63.8)	
p53-	27 (62.8)	42 (82.4)	118 (78.7)	628 (74.0)	0.034*, <0.0005**
p53+	16 (37.2)	9 (17.6)	32 (21.3)	221 (26.0)	
erbB2-	35 (81.4)	45 (84.9)	109 (82.6)	NA	
erbB2+	8 (18.6)	8 (15.1)	23 (17.4)	NA	

*BRCA1 versus non-BRCA1/2 tumours; **BRCA1 versus unselected breast tumours; ***BRCA2 versus unselected breast tumours; ****non-BRCA1/2 tumours versus unselected breast tumours.

Ca, carcinoma; ER, oestrogen receptor; NA, not available; PgR, progesterone receptor.